2017
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, X. C, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research 2017, 23: 4190-4202. PMID: 28298546, PMCID: PMC6790129, DOI: 10.1158/1078-0432.ccr-16-3193.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBone NeoplasmsBrain NeoplasmsBreast NeoplasmsCell Membrane PermeabilityCopper RadioisotopesCyclophosphamideDoxorubicinFemaleHumansLiverMiddle AgedNanoparticlesNeoplasm MetastasisPolyethylene GlycolsPositron Emission Tomography Computed TomographyReceptor, ErbB-2SpleenTrastuzumabConceptsPET/CTHER2-positive metastatic breast cancerMetastatic breast cancerFavorable treatment outcomesRetrospective exploratory analysisClin Cancer ResHuman metastatic tumorsEPR effectMetastatic tumorsClinical trialsPatient outcomesBrain lesionsTreatment outcomesBreast cancerClinical studiesDrug levelsPreclinical studiesTumor lesionsSolid tumorsPatientsBackground uptakeTherapeutic nanoparticlesCancer ResTumorsHuman tumors
2013
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research 2013, 19: 1512-1524. PMID: 23340294, PMCID: PMC3602220, DOI: 10.1158/1078-0432.ccr-11-3326.Peer-Reviewed Original ResearchConceptsBreast cancer stem cellsGamma-secretase inhibitorsAdvanced breast cancerClinical trialsBreast cancerSecretase inhibitorsMaximum-tolerated doseEfficacy of docetaxelSerial tumor biopsiesNotch pathwayTumors of patientsDoses of MKConcurrent clinical trialsHuman breast tumorsNotch pathway inhibitorsCancer stem cellsManageable toxicityTumorgraft modelsDocetaxel treatmentBCSC markersSerial biopsiesConventional therapyPreclinical dataClinical studiesExperimental therapies